Abacus Health Products Partners with Gillette Stadium and Patriot Place to Increase Awareness of CBDMEDIC
WOONSOCKET, R.I. and TORONTO, Ontario – October 25, 2019 – Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced an agreement with Gillette Stadium and Patriot Place to promote awareness of its CBDMEDIC brand.
The three-tiered partnership includes elements of branding, activation and hospitality for the 2019 and 2020 seasons. This partnership further enhances the recently announced relationship between three-time champion Rob Gronkowski and Abacus. Gronkowski was one of the best and most recognized players during his nine-year professional football career and nowhere was he more popular than at home at Gillette Stadium and Patriot Place.
With approximately 15 million people living in New England, Abacus has targeted this regional location to drive awareness of the CBDMEDIC brand and expects that its activities will also lead to an increase in its national brand awareness. As part of the sponsorship with Patriot Place, Abacus has the opportunity to sample its CBDMEDIC products to the attendees of Gillette Stadium events. Additionally, over the course of the next several months, CBDMEDIC branding will be placed across several high visibility locations outside Gillette Stadium and throughout Patriot Place.
Abacus is confident that its partnership with Gillette Stadium and Patriot Place will support its efforts in building CBDMEDIC as a nationally recognized brand.
“Abacus is excited to be joining forces with Gillette Stadium and Patriot Place,” said Perry Antelman, CEO of Abacus Health Products. “We see this as a substantial initiative to advocate for the use of CBD for all athletes and Americans suffering from pain.”
This news release contains forward-looking statements or information (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements.
The forward-looking statements contained in this news release include, without limitation, statements relating to the increase in awareness of the Company’s products and the execution of the Company’s growth strategy, and are based on management’s current expectations and are subject to a number of risks, uncertainties and assumptions, including assumptions regarding the Company’s ability to efficiently operate its business, market and economic conditions, business prospects or opportunities, future plans and strategies, anticipated events and trends, and regulatory changes that may affect the Company and its customers and industry. There can be no assurance that actual results will not differ materially from those expressed or implied in forward-looking statements. Undue reliance should not be placed on forward-looking statements. Additional information about these risks, uncertainties and assumptions is contained under “Risk Factors and Uncertainties” in the Company’s annual information form dated April 12, 2019, which is available under the Company’s SEDAR profile at www.sedar.com. Each forward-looking statement speaks only as of the date hereof, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
About Abacus Health Products, Inc.
Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.
To learn more about Abacus, visit www.abacushp.com
For further information:
Hank Hague, Chief Financial Officer
Email: [email protected]
Bill Mitoulas, Investor Relations
Email: [email protected]